DelveInsight releases an in-depth cerebral amyloid angiopathy (CAA) market analysis for the 7MM through 2034. The report highlights the absence of approved therapies, Alnylam Pharmaceuticals’ Mivelsiran pipeline asset, the impact of aging populations, and the significant disease burden, with 46% of mild-to-severe cases in Western populations and notable gender disparities. Cerebral...